文献速递流行病学与生物统计真实世界研究与卫生经济

阿片类替代治疗期间及之后死亡风险:队列研究的系统综述与Meta分析

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
PubMed 文献 · BMJ · 2017-04-26

该系统综述与Meta分析纳入19项队列,比较美沙酮或丁丙诺啡替代治疗期间与治疗外的全因及过量死亡风险。美沙酮治疗外与治疗内的全因死亡率比为3.20(95%CI 2.65至3.86),丁丙诺啡为2.20(1.34至3.61)。结论认为保留治疗与死亡风险大幅降低相关,但诱导期及停药后早期风险升高。

要点

  • 美沙酮治疗外与治疗内全因死亡率比为3.20(95%CI 2.65至3.86)。
  • 丁丙诺啡治疗外与治疗内全因死亡率比为2.20(95%CI 1.34至3.61)。
  • 美沙酮诱导期及两种药物停药后早期死亡风险升高。

核心结论

  • 保留美沙酮和丁丙诺啡治疗与阿片依赖者全因及过量死亡风险大幅降低相关。
  • 美沙酮诱导期及两种药物停药后即刻是死亡风险特别升高的时期,需公共卫生和临床策略应对。
  • 作者认为这些发现可能重要,但需进一步研究以妥善处理死亡率比较中的潜在混杂和选择偏倚。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase、PsycINFO和LILACS至2016年9月。
  • 纳入报告美沙酮或丁丙诺啡替代治疗期间及治疗外随访死亡的前瞻性或回顾性队列研究。
  • 共纳入19项合格队列,美沙酮治疗122885人随访1.3至13.9年,丁丙诺啡治疗15831人随访1.1至4.5年。
  • 由两名独立评价者提取数据并评估研究质量,采用多变量随机效应Meta分析联合合并治疗内外死亡率。

主要发现

  • 美沙酮治疗内与治疗外全因死亡率分别为每1000人年11.3和36.1(未调整治疗外与治疗内率比3.20,95%CI 2.65至3.86)。
  • 丁丙诺啡治疗内与治疗外全因死亡率分别为每1000人年4.3和9.5(未调整治疗外与治疗内率比2.20,95%CI 1.34至3.61)。
  • 美沙酮治疗内与治疗外过量死亡率分别为每1000人年2.6和12.7(未调整治疗外与治疗内率比4.80,95%CI 2.90至7.96)。
  • 丁丙诺啡治疗内与治疗外过量死亡率分别为每1000人年1.4和4.6。
  • 合并趋势分析中,美沙酮治疗前四周全因死亡率急剧下降,停药两周后逐渐下降;丁丙诺啡诱导期及剩余治疗期间全因死亡率保持稳定。

临床怎么用

  • 作者建议公共卫生和临床策略应应对美沙酮诱导期及两种药物停药后早期死亡风险升高的问题。

局限性

  • 作者指出需进一步研究以妥善处理替代治疗间及治疗内外死亡率比较中的潜在混杂和选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment.Design Systematic review and meta-analysis.Data sources Medline, Embase, PsycINFO, and LILACS to September 2016.Study selection Prospective or retrospective cohort studies in people with opioid dependence that reported deaths from all causes or overdose during follow-up periods in and out of opioid substitution treatment with methadone or buprenorphine.Data extraction and synthesis Two independent reviewers performed data extraction and assessed study quality. Mortality rates in and out of treatment were jointly combined across methadone or buprenorphine cohorts by using multivariate random effects meta-analysis.Results There were 19 eligible cohorts, following 122 885 people treated with methadone over 1.3-13.9 years and 15 831 people treated with buprenorphine over 1.1-4.5 years. Pooled all cause mortality rates were 11.3 and 36.1 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 3.20, 95% confidence interval 2.65 to 3.86) and reduced to 4.3 and 9.5 in and out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment.Conclusions Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids. The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017. PMID: 28446428. doi:10.1136/bmj.j1550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。